Wondering whether Lonza Group at about CHF 508 per share still makes sense for your portfolio, or if better value is available elsewhere? The stock has been fairly volatile recently, with a 4.8% decline over the last week, an 8.7% gain over the last month, and returns of 5.1% lower year to date and 8.9% lower over the last year. Recent coverage has focused on how Lonza Group fits into the wider life sciences sector and what that might mean for investor sentiment. This news context helps...

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...

Key Insights Lonza Group's estimated fair value is CHF412 based on 2 Stage Free Cash Flow to Equity Lonza Group is...

Most readers would already be aware that Lonza Group's (VTX:LONN) stock increased significantly by 8.8% over the past...

Investing.com - Shares of Lonza spiked in early European trading on Thursday after the Swiss contract pharmaceutical firm confirmed a "significant" long-term commercial supply agreement at one of the world’s largest manufacturing sites for biologic drugs in the United States.

Lonza Group AG ( VTX:LONN ) saw significant share price movement during recent months on the SWX, rising to highs of...

PHG vs. LZAGY: Which Stock Is the Better Value Option?

Lonza Group (LZAGY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Key Insights Lonza Group's significant individual investors ownership suggests that the key decisions are influenced by...